SAN DIEGO – Medtrade exhibitor Resmed has appointed Carol Burt as new lead director, set to take effect on Nov. 15, 2026. She will succeed Ron Taylor, Resmed’s current lead director, who is not standing for reelection at the company’s 2026 Annual Meeting of Stockholders on Nov, 18, 2026. Taylor will retire after more than 21 years of service to the company.
Burt has served on Resmed’s Board since 2013 and currently chairs the Nominating and Governance Committee. She is also a member of the Audit Committee and the Compliance, Privacy and Quality Committee. Burt’s extensive board leadership and governance experience position will serve her well as she continues to execute the company’s long-term strategy.
“Carol is an outstanding leader with deep governance experience, broad healthcare industry knowledge and a strong commitment to Resmed’s mission,” said Mick Farrell, Resmed’s chairman and CEO. “I look forward to continuing to work closely with Carol and the entire Board as we advance our strategy and create long-term value for our shareholders.”
Taylor joined Resmed’s Board of Directors in 2005 and has served in numerous leadership roles, including as lead director since 2013. During his tenure, Taylor helped guide the company’s governance, strategy and long-term growth while providing thoughtful leadership and independent oversight during a period of significant growth and transformation.
“Ron has made extraordinary contributions to Resmed over the past two decades,” added Farrell. “His integrity, sound judgment and unwavering commitment to our patients, employees and shareholders have helped shape Resmed. On behalf of the Board and all Resmedians, I thank Ron for his outstanding service and wish him and his family all the very best.”